IVERIC bio, Inc. (ISEE): Price and Financial Metrics
GET POWR RATINGS... FREE!
ISEE Stock Price Chart Interactive Chart >
ISEE Price/Volume Stats
| Current price | $22.75 | 52-week high | $24.56 |
| Prev. close | $23.24 | 52-week low | $8.85 |
| Day low | $22.65 | Volume | 1,139,800 |
| Day high | $23.66 | Avg. volume | 1,798,029 |
| 50-day MA | $21.44 | Dividend yield | N/A |
| 200-day MA | $16.19 | Market Cap | 2.75B |
IVERIC bio, Inc. (ISEE) Company Bio
IVERIC bio, Inc. (formerly Ophthotech Corporation) is a biopharmaceutical company specializing in the development of novel therapeutics to treat back of the eye diseases, with a focus on developing innovative therapies for age-related macular degeneration (AMD). The company was founded in 2007 and is based in New York, New York.
Latest ISEE News From Around the Web
Below are the latest news stories about IVERIC BIO INC that investors may wish to consider to help them evaluate ISEE as an investment opportunity.
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PARSIPPANY, N.J., February 02, 2023--Iveric Bio granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to 16 newly-hired, non-executive employees. |
Insiders who bought IVERIC bio, Inc. (NASDAQ:ISEE) last year must be regretting not buying more as market cap hits US$2.8bLast week, IVERIC bio, Inc. ( NASDAQ:ISEE ) insiders, who had purchased shares in the previous 12 months were rewarded... |
RTP gene therapy startup expands pipeline through deal with public biotechMore than a year after launching, a gene therapy company in the Research Triangle Park area has expanded its pipeline through a deal with a public biotech. |
Iveric Bio Announces the Addition of Pravin U. Dugel, MD, to its Board of DirectorsPARSIPPANY, N.J., January 03, 2023--Iveric Bio announced the election of Pravin U. Dugel, MD, President of Iveric Bio, to its Board of Directors, effective as of January 1, 2023. |
ISEE stock gains on deal to out-license gene therapy candidates (NASDAQ:ISEE)Clinical-stage biotech IVERIC bio (ISEE), has sold the ownership rights for preclinical stage gene therapy candidates IC-100 and IC-200 to for cash and stock. Read the full story here. |
ISEE Price Returns
| 1-mo | 15.13% |
| 3-mo | 16.61% |
| 6-mo | 74.60% |
| 1-year | 51.57% |
| 3-year | 223.38% |
| 5-year | 698.25% |
| YTD | 6.26% |
| 2022 | 28.05% |
| 2021 | 141.97% |
| 2020 | -19.46% |
| 2019 | 615.00% |
| 2018 | -61.54% |
Loading social stream, please wait...